Cellectis SA (0WA2) AI Stock Analysis

Cellectis SA

(LSE:0WA2)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Allogeneic therapy platformAn allogeneic, off-the-shelf approach could support broader and more scalable cell-therapy delivery than individualized treatments if clinical development succeeds. The combination of engineered T-cell research and associated manufacturing capabilities gives Cellectis an integrated platform for advancing multiple therapeutic programs.

Negative Factors

Revenue contractionDeclining TTM revenue weakens the near-term foundation for funding research and clinical development, particularly because Cellectis has limited recurring product sales and relies heavily on collaboration-related economics. Revenue volatility also makes it harder to plan investment and assess the pace at which the business can scale.

Cellectis SA (0WA2) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: EUR 250.97M
Dividend Yield: ―
Average Volume (3M): 2,275
Price to Earnings (P/E): -1.8
Beta (1Y): 0.34
Revenue Growth: -5.98%
EPS Growth: -8.67%
Country: UK
Employees: 227
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Cellectis SA Business Overview & Revenue Model

Company Description

Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric...

Cellectis SA Earnings Call Summary

Earnings Call Date:Aug 03, 2025(Q2-2025)|% Change Since:-61.93%|Next Earnings Date:Nov 08, 2026

Earnings Call SentimentPositive

The earnings call highlighted significant progress in advancing pivotal clinical trials and maintaining a strong financial position, with ongoing collaborations and upcoming strategic events. However, ongoing arbitration and a decrease in cash reserves posed challenges.

Positive Updates

Initiation of Pivotal Phase II Trial for lasme-cel

Cellectis is preparing to initiate the pivotal Phase II trial for lasme-cel (UCART22) in relapsed or refractory acute lymphoblastic leukemia in the second half of 2025, following successful end of Phase I discussions with the FDA and EMA.

Negative Updates

Servier Arbitration

Cellectis is engaged in arbitration with Servier regarding the termination of a licensing agreement, seeking compensation for losses due to lack of development of licensed products. The decision is expected by December 15, 2025.

Company Guidance

During Cellectis' Second Quarter 2025 Earnings Call, the company provided guidance on several key metrics. They announced the completion of end-of-Phase I discussions with the FDA and EMA for lasme-cel, UCART22, in relapsed or refractory acute lymphoblastic leukemia, and their preparation to initiate a pivotal Phase II trial in the second half of 2025. Additionally, the NatHaLi-01 study on UCART20x22 is progressing, with Phase I data anticipated by late 2025. Cellectis is advancing three cell and gene therapy programs under their partnership with AstraZeneca. Financially, the company reported cash, cash equivalents, and fixed-term deposits of $230 million as of June 30, 2025, which are expected to fund operations into the second half of 2027. They are also involved in arbitration with Servier, with a decision expected by December 15, 2025. The company will provide further insights and data during their Investor R&D Day on October 16, 2025.

Cellectis SA Risk Analysis

Cellectis SA disclosed 102 risk factors in its most recent earnings report. Cellectis SA reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks

1.Cellectis S.A. may experience substantial future dilution as a result of future equity offerings by Calyxt.Q4, 2021

2.Certain rights under the Stockholder’s Agreement with Calyxt terminate when Cellectis S.A.’s ownership level falls below 50%.Q4, 2021

3.Calyxt has a limited operating history, which makes it difficult to evaluate its current business and prospects and may increase the risk of an investment in Calyxt.Q4, 2021

Cellectis SA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0WA2 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FR:IPH	47Neutral	EUR 140.30M	-2.46	152.56%	―	-29.48%	7.91%
FR:NANO	46Neutral	EUR 1.43B	-25.56	89.71%	―	―	―
FR:TNG	46Neutral	EUR 202.03M	-4.34	-29.36%	―	189.81%	38.50%
FR:OSE	43Neutral	EUR 45.93M	-1.16	-96.73%	―	-96.25%	-197.89%
FR:MAAT	39Underperform	EUR 19.20M	-0.53	―	―	-19.02%	10.39%

* Healthcare Sector Average

Performance Comparison

GB:0WA2 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0WA2	Cellectis SA	1.05	-1.86	-64.02%
FR:IPH	Innate Pharma S.A.	1.26	-0.39	-23.51%
FR:NANO	Nanobiotix SA	28.12	12.36	78.43%
FR:TNG	Transgene SA	0.73	-0.63	-46.62%
FR:OSE	OSE Immunotherapeutics	1.95	-3.75	-65.75%
FR:MAAT	MaaT Pharma	1.02	-3.25	-76.16%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Cellectis SA AI Stock Analysis